Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer

Evaluation of Amino Acid Metabolism Changes in Participants With Ovarian Cancer by Dynamic Test

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Ovarian cancer is associated with undernutrition in more than half of all cases. The current management of undernutrition-cachexia in cancer is not specific. It is well recognized that the nutritional support currently offered to cancer patients is not effective in combating cachexia, which progresses inexorably, leading to the patient's death. It is therefore necessary to offer specific and adapted care, in particular by optimizing the quality of nitrogen intake. To achieve this, the investigators first need to define the specific amino acid requirements of cancer patients.

Who May Be Eligible (Plain English)

Who May Qualify: - Histological diagnosis of high-grade serous ovarian cancer not immediately resectable (stage III or IVa) managed at Grenoble Alpes University Hospital. - Affiliation to the French social security system. - Able to understand and follow the instructions necessary for the conduct of the trial, and having given written consent for the study. Who Should NOT Join This Trial: - Significant active comorbidity requiring long-term drug treatment (e.g. organ failure, diabetes) or history of pathology likely to impact amino acid metabolism (e.g. urea or homocysteine cycle abnormalities, tyrosinemia, alkaptonuria, hyperprolinemia, organic aciduria). - vegetarian or vegan diet - difficult venous access - Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, persons subject to a legal protection measure). - Subject receiving more than 4,500 euros in compensation for participation in other research involving the human body in the 12 months preceding this study. - Significant biological abnormalities (not explained by the underlying pathology for women with ovarian cancer) - Liver metastases Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Histological diagnosis of high-grade serous ovarian cancer not immediately resectable (stage III or IVa) managed at Grenoble Alpes University Hospital. * Affiliation to the French social security system. * Able to understand and follow the instructions necessary for the conduct of the trial, and having given written consent for the study. Exclusion Criteria: * Significant active comorbidity requiring long-term drug treatment (e.g. organ failure, diabetes) or history of pathology likely to impact amino acid metabolism (e.g. urea or homocysteine cycle abnormalities, tyrosinemia, alkaptonuria, hyperprolinemia, organic aciduria). * vegetarian or vegan diet * difficult venous access * Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, persons subject to a legal protection measure). * Subject receiving more than 4,500 euros in compensation for participation in other research involving the human body in the 12 months preceding this study. * Significant biological abnormalities (not explained by the underlying pathology for women with ovarian cancer) * Liver metastases

Treatments Being Tested

OTHER

dynamic test for amino acid metabolism

Subjects are fasting, and the dynamic test is performed as follows: Placement of 1 peripheral venous line (for infusions). * H0-H1.5: infusion of a 10% glucose solution at increasing flow rate (3 steps of 30 min each: 0.06g/kg/h then 0.12g/kg/h then 0.25g/kg/h of glucose) * H1,5: initial blood sampling (amino acid assay) * H1.5-H4.5: infusion of amino acid solution (Aminoven 5%, Fresenius Kabi, Sèvres, France) at constant speed (flow rate 10.5 mg/kg/h of nitrogen or 1.30 ml/kg/H) in Y with glucose infusion (0.25g/kg/h of glucose) * H4.5: Final blood sampling (amino acid assay) Each amino acid is plotted as a function of its perfusion rate on the abscissa and its variation in plasma concentration on the ordinate.

Locations (1)

CHU Grenoble Alpes
La Tronche, France